首页 | 本学科首页   官方微博 | 高级检索  
     

表柔比星-聚乳酸缓释微球局部治疗肝癌
引用本文:Zhou JY,Wang XM,Ye SF,Weng J,Hou ZQ,Zhou ZM,Zhang QQ. 表柔比星-聚乳酸缓释微球局部治疗肝癌[J]. 中国医学科学院学报, 2006, 28(5): 690-694
作者姓名:Zhou JY  Wang XM  Ye SF  Weng J  Hou ZQ  Zhou ZM  Zhang QQ
作者单位:1. 厦门大学,附属中山医院肝胆外科,厦门,361004
2. Research Center of Biomedical Engineering, Xiamen University, Xiamen 361004
3. Key Laboratory of Biomaterial of Tianjin, Institute of Biomedical Engineering, CAMS and PUMC, Tianjin 300192
摘    要:目的研究表柔比星-聚乳酸缓释微球(EPI-PLA-MS)局部给药治疗肝癌的效果。方法复乳-溶剂挥发法制备EPI-PLA-MS。将40只昆明小鼠随机分为5组,每组8只,分别腹腔注射不同剂量的游离表柔比星(FEPI),计算最大耐受量(MTD)。H22皮下实体瘤肝癌荷瘤小鼠3组,每组5只,分别用生理盐水(normalsaline,NS)、空白微球和含药微球(含EPI9mg/kg)瘤内注射给药,2周后取瘤称重。H22腹水型肝癌荷瘤小鼠3组,每组5只,分别用NS、空白微球和含药微球(含EPI9mg/kg)腹腔注射给药,计算动物生命延长率。结果FEPI腹腔注射的MTD为9mg/kg。EPI-PLA-MS瘤内给药后含药微球组和空白微球组的抑瘤率分别为40.35%和36.09%。腹腔给药后能显著延长荷瘤鼠的生存时间,含药微球组和空白微球组生命延长率分别为153.49%和142.22%。结论EPI-PLA-MS是一种有效低毒的药物新剂型,在局部治疗肝癌方面具有良好的临床应用前景。

关 键 词:表柔比星  缓释剂,微球  肝肿瘤  局部治疗
文章编号:1000-503X(2006)05-0690-05
收稿时间:2006-03-13
修稿时间:2006-03-13

Treatment of hepatocellular carcinoma in mice with locally administered epirubicin-loaded poly(D, L)-lactic acid microspheres
Zhou Jian-yin,Wang Xiao-min,Ye She-fang,Weng Jian,Hou Zhen-qing,Zhou Zhi-min,Zhang Qi-qing. Treatment of hepatocellular carcinoma in mice with locally administered epirubicin-loaded poly(D, L)-lactic acid microspheres[J]. Acta Academiae Medicinae Sinicae, 2006, 28(5): 690-694
Authors:Zhou Jian-yin  Wang Xiao-min  Ye She-fang  Weng Jian  Hou Zhen-qing  Zhou Zhi-min  Zhang Qi-qing
Affiliation:Department of Hepatobiliary Surgery, Zhongshan Hospital, Xiamen University, Xiamen 361004, China
Abstract:OBJECTIVE: To study the effectiveness of treating hepatocellular carcinoma (HCC) in mice with locally administered epirubicin-loaded poly( D, L) - lactic acid microspheres (EPI-PLA-MS ). METHODS: EPI-PLA-MS was prepared with double emulsion solvent evaporation technique. Five groups of mice (n = 8 in each group) were intraperitoneally injected with five different doses of free epirubicin (FEPI), and the maximum tolerated dose (MTD) was calculated. Then 15 mice with transplanted subcutaneous H22 HCC were divided into three groups (n = 5), which were respectively intratumorally injected with normal saline (NS), blank microspheres, and EPI-PLA-MS (with 9 mg/kg of EPI). After two weeks the tumors were excised and weighed. Another 15 mice with transplanted H22 ascites HCC were divided into three groups (n = 5), which were intraperitonealy injected with the same drugs, and the increased life span were registered exactly. RESULTS: The MTD of intraperitoneally injected FEPI was 9 mg/kg. The tumour-inhibiting rates was 40.35% and 36.09% when EPI-PLA-MS were administered by intratumoral injection to the mice with subcutaneous H22 HCC. It significantly prolonged the survival time of mice with H22 ascites HCC and the increased life span by 153.49% and 142.22% when EPI-PLA-MS were intraperitoneally administered. CONCLUSION: EPI-PLA-MS is a new sustained-release preparation with high-efficacy and low-toxicity in treating HCC and has shown promising prospects when administered locally.
Keywords:epirubicin  sustained-release drug  microsphere  hepatocellular carcinoma  local treatment
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号